(Q37345849)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19072347%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

review article

1 reference

title

Role of nonalcoholic fatty liver disease in the development of insulin resistance and diabetes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19072347%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

0 references

1 reference

1 reference

metabolic dysfunction–associated steatotic liver disease

1 reference

Henning Grønbaek

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19072347%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Jørgen Rungby

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19072347%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Ole Schmitz

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19072347%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

1 October 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19072347%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Gastroenterology & Hepatology

18 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19072347%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19072347%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19072347%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

705-711

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19072347%20AND%20SRC:MED&resulttype=core&format=json

Nonalcoholic fatty liver disease: from steatosis to cirrhosis

18 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Long-term follow-up of patients with NAFLD and elevated liver enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Fatty liver: a novel component of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Nonalcoholic steatohepatitis: definition and pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Association of nonalcoholic fatty liver disease with insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Nonalcoholic fatty liver disease: a feature of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Contribution of metabolic factors to alanine aminotransferase activity in persons with other causes of liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Evaluation of blood donors with elevated serum alanine aminotransferase levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third National Health and Nutrition Survey (NHANES III).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Pediatric nonalcoholic fatty liver disease: a critical appraisal of current data and implications for future research

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Prevalence of fatty liver in children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Effects of nonalcoholic fatty liver disease on the development of metabolic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Chronological development of elevated aminotransferases in a nonalcoholic population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Primacy of Hepatic Insulin Resistance in the Development of the Metabolic Syndrome Induced by an Isocaloric Moderate-Fat Diet in the Dog

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Acquired obesity is associated with changes in the serum lipidomic profile independent of genetic effects--a monozygotic twin study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Dietary fat content modifies liver fat in overweight nondiabetic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

NASH: a mitochondrial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Regulation of plasma triglycerides in insulin resistance and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Mechanisms of Disease: hepatic steatosis in type 2 diabetes--pathogenesis and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Review: The role of insulin resistance in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Development of muscle insulin resistance after liver insulin resistance in high-fat-fed rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Metabolic lessons from genetically lean mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Mitochondrial abnormalities in non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Mitochondrial dysfunction and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Mitochondrial dysfunction in the elderly: possible role in insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Insulin resistance: a metabolic pathway to chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Beyond insulin resistance in NASH: TNF-alpha or adiponectin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Interleukin-6 induces cellular insulin resistance in hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Sterol regulatory element binding protein 1c (SREBP-1c) expression in human obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Role of ChREBP in hepatic steatosis and insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

ChREBP, a transcriptional regulator of glucose and lipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Mechanisms linking obesity to insulin resistance and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Treatment of non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

The effects of rosiglitazone, metformin, and diet with exercise in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy--a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705

Incretin mimetics as a novel therapeutic option for hepatic steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.705